Invention Grant
- Patent Title: Use of methylation sites in Y chromosome as prostate cancer diagnosis marker
-
Application No.: US15544735Application Date: 2015-12-30
-
Publication No.: US10648039B2Publication Date: 2020-05-12
- Inventor: Yingli Sun , Lushuai Yao
- Applicant: WUXI SHENRUI BIO-PHARMACEUTICALS CO., LTD.
- Applicant Address: CN Wuxi, Jiangsu
- Assignee: WUXI SHENRUI BIO-PHARMACEUTICALS CO., LTD.
- Current Assignee: WUXI SHENRUI BIO-PHARMACEUTICALS CO., LTD.
- Current Assignee Address: CN Wuxi, Jiangsu
- Agency: Dann, Dorfman, Herrell & Skillman
- Agent Robert C. Netter, Jr.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@17dc1f1e
- International Application: PCT/CN2015/099922 WO 20151230
- International Announcement: WO2016/115967 WO 20160728
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6886 ; C12Q1/6809 ; C12Q1/6872

Abstract:
Disclosed is a use of methylation sites as a disease diagnosis marker, in particular relating to a use of methylation sites in a Y chromosome as a prostate cancer diagnosis marker. More particularly, the method and criterion for screening methylation sites in chromosomes associated with a disease are established in the present invention, and using prostate cancer as an example, six methylation sites in the Y chromosome associated with the prostate cancer diagnosis are screened out. Methylation sites in the Y chromosome screened can be used for early and rapid diagnosis of the disease as a prostate cancer diagnosis marker.
Public/Granted literature
- US20170362663A1 USE OF METHYLATION SITES IN Y CHROMOSOME AS PROSTATE CANCER DIAGNOSIS MARKER Public/Granted day:2017-12-21
Information query